Effect of GLP‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: a randomized, placebo‐controlled trial

AIMS: Schizophrenia is associated with cardiovascular co‐morbidity and a reduced life‐expectancy of up to 20 years. Antipsychotics are dopamine D(2) receptor antagonists and are the standard of medical care in schizophrenia, but the drugs are associated with severe metabolic side effects such as obe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishøy, Pelle L., Knop, Filip K., Broberg, Brian V., Bak, Nikolaj, Andersen, Ulrik B., Jørgensen, Niklas R., Holst, Jens J., Glenthøj, Birte Y., Ebdrup, Bjørn H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299524/
https://www.ncbi.nlm.nih.gov/pubmed/27717222
http://dx.doi.org/10.1111/dom.12795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299524/
https://www.ncbi.nlm.nih.gov/pubmed/27717222
http://dx.doi.org/10.1111/dom.12795

Ejemplares similares